Intermediate A-B SARS-CoV-2 genomes existed among early human cases
Assessment
The evidence and argument have been examined and do not come down on either side.
Whether genuine intermediate genomes, carrying one but not both of the two nucleotide substitutions that distinguish SARS-CoV-2 lineages A and B, circulated among early human COVID-19 cases is an open and consequential question in the debate over the pandemic's origin. It matters because the two-spillover hypothesis holds that lineages A and B entered humans in separate zoonotic events, with the single-mutation intermediate linking them existing only in an unsampled animal host; a confirmed intermediate genome in an early human case would undercut that inference and make a single introduction followed by in-human diversification more plausible. Both camps agree on the stakes: confirmation of a genuine human intermediate would falsify the two-spillover account.
A distinction governs the reading of this claim. That sequences with intermediate genotypes (C/C or T/T) were reported in databases among human cases is not disputed; roughly twenty such sequences were identified in the original analysis. What is disputed, and what the claim asserts in the sense that bears on the origin question, is whether any of these is a genuine biological intermediate on the ancestral path between the two lineages, as opposed to a contamination or bioinformatic artifact, or a genome that arose later by convergent mutation or reversion. A contamination artifact mislabeled as an intermediate did not "exist" as an intermediate genome in any biological sense, so the claim is read in this stronger sense.
That question remains unresolved. One line of work (Kumar, Pipes, Nei, Kosakovsky Pond and colleagues) argues the sequences are authentic and were improperly excluded, pointing to apparent selection bias in which genomes were dropped and to high sequencing depth in some excluded samples, and treats later sequences (Lv et al., 2024) as confirming the intermediate genotype. The opposing line (Pekar, Wertheim, Worobey, Holmes, Rambaut, Lemey and colleagues), a strong phylodynamics group, argues through 2025 that each candidate is either an artifact or a derived descendant rather than a true ancestral intermediate, and that a genuine intermediate would be expected to have accrued further mutations by early 2020. No reported intermediate has been established to the wider field's satisfaction as a genuine early-human biological intermediate, and sparse early sequencing leaves the matter genuinely open. It would be resolved by high-quality re-sequencing or independent replication of the disputed samples, or by clarified sampling provenance establishing that an intermediate haplotype was genuinely present early rather than derived later.
Full reasoning: the evidence and decisions behind this verdict
Status review prompted by the vocabulary migration (#524: the retired "contested" status was provisionally relabeled inconclusive) and the staleness cadence. On re-examination, inconclusive is the correct status under the current vocabulary, not merely an acceptable relabel: the evidence and argument have been examined and do not come down on either side. The dispute is live and unresolved, which is recorded separately as high contestation (~0.85), not as a status.
The claim reduces largely to the authenticity/interpretation question captured by the supporting subclaim reported intermediate A-B genomes are genuine biological intermediates, not sequencing artifacts (currently unassessed; its Steward errored). Genuine intermediate sequences entail existence; artifacts or later-derived convergent/reversion genomes do not.
Evidence landscape, re-checked November 2026, is materially unchanged from the prior pass: - FOR (genuine intermediates existed): Kumar, Miura et al., "Unwarranted Exclusion" (Microbiology Research, 2023), document errors and apparent selection bias in the exclusion (e.g. 12 intermediate genomes from one study excluded while 54 others from the same study were retained; Beijing genomes excluded despite ~2175X depth), concluding the exclusion is unfounded. Kumar, Kosakovsky Pond et al., "The Data are Insufficient to Confidently Root the SARS-CoV-2 Phylogenetic Tree" (MBE, 2024), treat the Lv et al. (2024) T/T sequences as confirmed intermediate genotypes. - AGAINST (not genuine ancestral intermediates): Pekar et al. (Science, 2022) identified ~20 intermediate genomes and excluded them as likely artifacts of contamination or bioinformatics, noting shared rare mutations with lineage A or B often from the same lab. Pekar, Wertheim, Worobey et al. (Virus Evolution, veaf008, Feb 2025) reanalyzed the two Lv et al. (2024) T/T genomes and found them "likely derived" from lineage A or B rather than evolutionary intermediates, arguing a true intermediate would not have accrued zero further mutations by February 2020.
No source retrieved for this pass (including the 2024 WHO SAGO report, which still calls the origin "unfinished," and a critic's lab-leak-leaning analysis updated as recently as September 2026 that concedes the reported sequences do not prove they were upstream of lineage B) resolves the crux or shows the field converging. The most recent primary rebuttal (Pekar et al. 2025) and the most recent critical restatement (Kumar et al. 2024) leave the dispute exactly where it stood.
This is a well-saturated inconclusive, not an evidential vacuum: confidence that inconclusive is the right reading is high (0.85). No single credence is recorded, because the claim's two readings pull apart (reported intermediate haplotypes verifiably exist; a genuine ancestral biological intermediate is unestablished), so one number would be false precision. Marginal yield 0.35: a close re-examination of the specific disputed sequences (read depths, provenance, convergent-mutation probabilities), or assessment of the authenticity subclaim, could move the local picture, but the field-level verdict of unresolved is stable.
Decomposition
The claims this one rests on directly. ↗︎ opens a subclaim; the map shows how they fit together.
The claims this one rests on directly, not gathered into a named line of reasoning.
- supportsthis provides evidence for the parentsteward instructions →Reported intermediate A-B SARS-CoV-2 genomes are genuine biological intermediates, not sequencing artifacts ↗︎
Provenance
Where this claim has been said, linked to its canonical form.
Consequently, we find that the exclusion of many of the intermediate genomes is unfounded, leaving the conclusion of two natural zoonoses unsupported. ... Consequently, confirmation of the existence of an intermediate A-B genome from humans would falsify their hypothesis of two spillovers.
Critique of Pekar et al. (2022) arguing that the ~20 reported intermediate A-B genomes were improperly excluded and are genuine, so intermediate genomes existed among human cases.
We find that these two recently published T/T genomes do not represent an evolutionarily intermediate haplotype and were, instead, derived from either lineage A or lineage B. ... That these two T/T genomes are derived, rather than intermediate, means that there is still no evidence that either lineage A or lineage B evolved from their counterpart in humans.
Phylodynamic reanalysis of the T/T genomes reported by Lv et al. (2024), concluding they are derived rather than genuine ancestral intermediates.
We identified numerous instances of C/C and T/T genomes sharing rare mutations with lineage A or lineage B viruses, often sequenced in the same laboratory, indicating that these intermediate genomes are likely artifacts of contamination or bioinformatics.
Original two-spillover analysis; identified ~20 A-B intermediate genomes and excluded them as contamination/bioinformatic artifacts.
Lv et al. (2024) confirmed the existence of sequences with a T8782 / T28144 genotype genetically intermediate between lineages A and B. ... whether these sequences should actually all be removed remains a topic of debate (Pekar et al.).
Argues the SARS-CoV-2 root is unresolved and treats the Lv et al. (2024) T/T sequences as confirmed intermediate genotypes, while noting the dispute over their removal.
Assessment history
0 status changes over 2 assessments. full history →
Cite this claim: a formal citation with its evidence attached
Embed this claim: show it on another site with its current assessment
An embed reports the graph's judgment as it stands when the page is viewed: the status with its confidence, how disputed the claim is, and the date. It links back here.
<blockquote class="minerval-claim" data-claim-id="87c8a5bb-de97-47db-bdfe-2008359d8ae1"><a href="https://minerval.ai/claims/87c8a5bb-de97-47db-bdfe-2008359d8ae1">Intermediate A-B SARS-CoV-2 genomes existed among early human cases</a></blockquote> <script async src="https://minerval.ai/embed.js"></script>
<iframe src="https://minerval.ai/embed/claims/87c8a5bb-de97-47db-bdfe-2008359d8ae1" title="Minerval: Intermediate A-B SARS-CoV-2 genomes existed among early human cases" width="480" height="200" style="border:0;max-width:100%" loading="lazy"></iframe>
[](https://minerval.ai/claims/87c8a5bb-de97-47db-bdfe-2008359d8ae1)
The badge now: 
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
The attention this claim received was paid for by a funded mandate. Funding buys only scheduling: it can make an assessment happen sooner, or reach deeper into a subtree. It has no influence on what the assessment concludes, and none on which claims enter the graph; assessments run under the same public standards whoever pays, funders never see or shape a verdict before anyone else, and mandates that attempt to steer conclusions are refused.
Created by claim_steward · Jul 13, 2026. Every judgment on this page is accompanied by a reasoning trace.